the role of cyberknife by dr. david spellberg
TRANSCRIPT
![Page 1: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/1.jpg)
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of
Localized Prostate CancerDavid M. Spellberg M.D., FACSNaples Urology Associates, P.A.
Naples, Florida
![Page 2: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/2.jpg)
© Dr. David Spellberg
![Page 3: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/3.jpg)
TREATMENT OPTIONS
• WATCHFUL WAITING• SURGERY• RADIATION THERAPY• CRYOTHERAPY• HIFU• PROTON• HORMONAL MANIPULATION• CHEMOTHERAPY• EXPERIMENTAL
© Dr. David Spellberg
![Page 4: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/4.jpg)
RESEARCH
• INTERNET• LIBRARY• LOCAL CANCER SOCIETY• SUPPORT GROUPS• FAMILY/ FRIENDS
© Dr. David Spellberg
![Page 5: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/5.jpg)
© Dr. David Spellberg
![Page 6: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/6.jpg)
COMPLICATIONS OF TREATMENT
• INCONTINENCE• IMPOTENCE• EJACULATION DYSFUNCTION• BOWEL PROBLEMS• WORSENING OF OVERALL HEALTH
© Dr. David Spellberg
![Page 7: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/7.jpg)
PATIENT DRIVEN
• NON-INVASIVE• MINIMAL SIDE EFFECTS• MINIMAL DISRUPTION OF LIFE• EFFICACY
© Dr. David Spellberg
![Page 8: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/8.jpg)
• Frameless Radiosurgery
• Robotics
• Image Guidance• Advanced
Treatment Planning
CyberKnife Technology
© Dr. David Spellberg
![Page 9: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/9.jpg)
© Dr. David Spellberg
![Page 10: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/10.jpg)
• Precise control limits dose to the rectal wall and urethra
Prostate Radiosurgery
Image courtesy of San Diego CyberKnife Center
© Dr. David Spellberg
![Page 11: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/11.jpg)
• Patient lies comfortably on the
couch while the CyberKnife robot moves, images and treats.
• Treatments typically last 1 hour
• Most patients require no sedation allowing them to depart at the completion of their treatment
CyberKnife Treatment Delivery
© Dr. David Spellberg
![Page 12: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/12.jpg)
Radiation Options
Convenience Invasive Toxicity EfficacyIMRT Low No Mod HighLDR
BrachyTxHigh Yes X 1 Mod High
HDRBrachyTx
Moderate Yes X 2 Mod High
CK High No Very Low TBD© Dr. David Spellberg
![Page 13: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/13.jpg)
SEQUENCE OF EVENTS
• PATHOLOGY REVIEW• CT/BS REVIEW• DISCUSSION OF TREATMENT
OPTIONS• FIDUCIAL PLACEMENT• CYBERKNIFE TREATMENT
© Dr. David Spellberg
![Page 14: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/14.jpg)
FIDUCIAL PLACEMENT
• NPO• IV SEDATION• TRUS GUIDED TEMPLATE• ANTIBIOTICS
© Dr. David Spellberg
![Page 15: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/15.jpg)
© Dr. David Spellberg
![Page 16: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/16.jpg)
© Dr. David Spellberg
![Page 17: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/17.jpg)
© Dr. David Spellberg
![Page 18: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/18.jpg)
• Precise control limits dose to the rectal wall and urethra
• Automatic correction for target motion during treatment
Prostate Radiosurgery
Footage courtesy of St. Anthony’s Hospital
© Dr. David Spellberg
![Page 19: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/19.jpg)
Accuray Confidential
© Dr. David Spellberg
![Page 20: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/20.jpg)
• The prostate moves during treatment
240 seconds of Beam on time
5mm of motion
© Dr. David Spellberg
![Page 21: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/21.jpg)
CyberKnife® Treatment of Prostate Cancer
© Dr. David Spellberg
![Page 22: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/22.jpg)
Prostate PTV: gland expanded 5 mm in each direction except posteriorly where it is expanded 3
mm
© Dr. David Spellberg
![Page 23: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/23.jpg)
BED Calculations• External Beam Radiation Therapy / HDR
– BED = nd [ 1 + (d/ α/β) ]• Low Dose Rate Permanent Decaying Implants
– BED = (Ro/ λ) { 1 + [ Ro/(μ+ λ)(α/β)] }• Definitions of parameters
n = # fractionsd = daily doseRo = initial dose rate of implantλ = radioactive decay constant = 0.693/T1/2
T1/2 = radioactive half-life of isotope μ = repair rate constant = 0.693/t1/2
t1/2 = tissue repair half-time© Dr. David Spellberg
![Page 24: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/24.jpg)
Calculating BED For Low Risk CaP Monotherapy Treatment Regimens
• Biologically Equivalent Dose
• BED = D (1 + d/alpha beta ratio)
• D = total dose• d = dose/fraction• alpha/beta ratio = 1.5 for prostate 3 for late effects 10 for acute effects
• 81Gy IMRT/ 45fx / 9 weeks (BED 1.5 = 178.2, BED 3 = 129.6 )• HDR monoTx @ 9.5Gy X 4fx (BED 1.5 = 278.7, BED 3 = 158.3)• HDR monoTx @ 8.55Gy X 4fx (BED 1.5 = 229.1, BED 3 = 131.7)• HDR monoTx @ 7.25Gy X 6fx (BED 1.5 = 253.7, BED 3 = 148.6)• Cyberknife monoTx @ 7Gy X 5fx (BED 1.5 = 198.3, BED 3 = 116.7 ) • Cyberknife monoTx @ 7.25Gy X 5fx
(BED 1.5 = 211.5, BED 3 = 123.9 )© Dr. David Spellberg
![Page 25: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/25.jpg)
Dose Calculations for Cyberknife Stereotactic Body Radiation Therapy
• For CK, one can fractionate the therapy yet remain convenient and non-invasive for the patient
• CK doses are most like HDR, since the dose/fraction, total doses and time factors are similar
• SHARP trial from Virginia Mason Hospital with good results (33.5Gy/5fx)
• Thus, since we have intermediate and long term results with HDR, CK appears to be a well founded treatment option
© Dr. David Spellberg
![Page 26: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/26.jpg)
Basic Demographics• Ages 62 to 85• Stage cT1cNoMo to cT2bNoMo• All patients treated between 12/07/2004
and 12/31/2007• Total number of Patients = 213
© Dr. David Spellberg
![Page 27: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/27.jpg)
Hormonal Therapy
• 186 Patients treated without Hormonal therapy
• 27 Patients treated with Neoadjuvant Hormonal Therapy
© Dr. David Spellberg
![Page 28: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/28.jpg)
HistologyGleason grade 3 + 3 = 172 PatientsGleason grade 3 + 4 = 31 PatientsGleason grade 4 + 3 = 8 PatientsGleason grade 4 + 4 = 1 PatientGleason grade 5 + 4 = 1 Patient
© Dr. David Spellberg
![Page 29: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/29.jpg)
Prostate Volumes
Range = 15.5cc to 109cc Mean initial volume = 45.7 cc Median initial volume = 46.1 cc
© Dr. David Spellberg
![Page 30: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/30.jpg)
Prostate Cyberknife MonoTx Dose
Mean Dose = 3503 cGy (n=162) Median Dose = 3500 cGy Range = 3500cGy to 3755 cGy Number of Fractions = 5
© Dr. David Spellberg
![Page 31: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/31.jpg)
Initial PSA’s
Range = 1.1 to 17.2 ng/ml Mean initial PSA = 5.87 ng/ml Median initial PSA = 5.75 ng/ml
© Dr. David Spellberg
![Page 32: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/32.jpg)
PSA Response to Cyberknife
0
1
2
3
4
5
6
7
8
iPSA 1 mo 3 mo 6 mo 9 mo 12 mo 15 mo 18 mo 21 mo 24 mo 36 mo
Mean PSA+HTx PSA-HTx PSA
© Dr. David Spellberg
![Page 33: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/33.jpg)
Acute Toxicity
• Urinary hesitancy, urgency, frequency (Day 3-10)• Tenesmus/ rectal discomfort (Day 5-8)• Diarrhea (Day 5-8)
• Rx: Flomax Lomotil Decadron Anusol-HC supp.
© Dr. David Spellberg
![Page 34: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/34.jpg)
Acute Toxicity Scoring(IPSS/RAS/SHIM)
• Baseline, days 2 and 5, post-treatment day 10, 1 month and 4 months
• Acute effects generally return to baseline by 1 months
• Urinary symptoms more marked in patients with IPSS baseline scores >20
• No urethral strictures/ persistent rectal bleeding observed
© Dr. David Spellberg
![Page 35: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/35.jpg)
IPSS Scores After Cyberknife SBRT
0
5
10
15
20
25
30
35
Overall Low (0-10) Mod(11-20) High(21-35)
Day 0Day 2Day 5Day 101 Month4 Month12 Month24 Month36 month
© Dr. David Spellberg
![Page 36: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/36.jpg)
RAS and SHIM Scores after Cyberknife SBRT
0
5
10
15
20
25
RAS Scores Overall SHIMScores
High SHIM(20-25)
Day 0Day 2Day 5Day 101 Month4 Month12 Month24 month36 month
© Dr. David Spellberg
![Page 37: The Role of Cyberknife by Dr. David Spellberg](https://reader035.vdocuments.us/reader035/viewer/2022070600/58e966fc1a28abb45f8b64a1/html5/thumbnails/37.jpg)
Summary• Cyberknife is a new and innovative treatment
delivery technique for prostate cancer.• Cyberknife monotherapy produces an early decline of
PSA’s in low risk patients.• The acute toxicity of Cyberknife monotherapy is very
minimal compared to other radiation treatments.• Cyberknife therapy is a noninvasive and convenient
treatment option for patients with early stage prostate cancer.
• Prostate cancer patients treated with Cyberknife should continued to be enrolled and followed in research protocols, and the data collectively analyzed.
© Dr. David Spellberg